KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease Tables and Figures v KDIGO Board Members vi Reference Keys vii CKD Nomenclature viiii Conversion Factors ix Abbreviations and Acronyms x Notice Foreword Work Group Membership Abstract Summary of Recommendation Statements Introduction: The case for updating and context Chapter 1: Assessment of lipid status in adults with CKD Chapter 2: Pharmacological cholesterol-lowering treatment in adults Chapter 3: Assessment of lipid status in children with CKD Chapter 4: Pharmacological cholesterol-lowering treatment in children Chapter 5: Triglyceride-lowering treatment in adults Chapter 6: Triglyceride-lowering treatment in children Methods for Guideline Development Biographic and Disclosure Information Acknowledgments References http://www.kidney-international.org contents & 2013 KDIGO VOL 3 | ISSUE 3 | NOVEMBER 2013 This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE) www.publicationethics.org TABLES Table 1. Secondary causes of dyslipidemias Table 2. Examples of situations in which measuring cholesterol level might or might not change the management implied by Recommendation 1.2 Table 3. Rate of coronary death or non-fatal MI (by age and eGFR) Table 4. Recommended doses of statins in adults with CKD Table 5. Plasma lipid concentrations for children and adolescents Table 6. Systematic review topics and screening criteria Table 7. Hierarchy of outcomes Table 8. Literature yield for RCTs Table 9. Work products for the guideline Table 10. Classification of study quality Table 11. GRADE system for grading quality of evidence Table 12. Final grade for overall quality of evidence Table 13. Balance of benefits and harms Table 14. KDIGO nomenclature and description for grading recommendations Table 15. Determinants of strength of recommendation Table 16. The Conference on Guideline Standardization (COGS) checklist for reporting clinical practice guidelines FIGURES Figure 1. 